Liraglutide for the Treatment of Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Placebo-Controlled Trials

Advances in Therapy

Volumn 31, Issue 11, 2014, Pages 1182-1195

  Du, Qiang ^a   Wang, Yan Jun ^a   Yang, Sheng ^a   Zhao, Yue Yang ^a   Han, Ping ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Glucagon like peptide 1; Liraglutide; Meta analysis; Randomized controlled trial; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LIRAGLUTIDE; PLACEBO; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2 RECEPTOR; GLYCOSYLATED HEMOGLOBIN;

ARTICLE; COCHRANE LIBRARY; DIET RESTRICTION; DRUG EFFECT; DRUG HALF LIFE; DRUG INDICATION; EMBASE; GLUCOSE BLOOD LEVEL; HUMAN; INFORMATION RETRIEVAL; MEDLINE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION; AGONISTS; ANALOGS AND DERIVATIVES; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; OUTCOME ASSESSMENT;

BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-2 RECEPTOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; OUTCOME ASSESSMENT (HEALTH CARE); RANDOMIZED CONTROLLED TRIALS AS TOPIC; WEIGHT LOSS;

EID: 84913583661     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-014-0164-2     Document Type: Article

References (37)

1. Unwin N, Guariguata L, Whiting D, et al. Complementary approaches to estimation of the global burden of diabetes. Lancet. 2012;379:1487–8.
2. Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137–49.
3. Rosberger DF. Diabetic retinopathy: current concepts and emerging therapy. Endocrinol Metab Clin North Am. 2013;42:721–45.
4. Lim AKh. Diabetic nephropathy—complications and treatment. Int J Nephrol Renovasc Dis. 2014;7:361–81.
5. Xu Q, Pan J, Yu J, et al. Meta-analysis of methylcobalamin alone and in combination with lipoic acid in patients with diabeticperipheral neuropathy. Diabetes Res Clin Pract. 2013;101:99–105.
6. Williams B. Blood pressure and diabetes: a fatal attraction. Eur Heart J. 2013;34:3395–7.
7. Lachin JM, Orchard TJ. Nathan DM; DCCT/EDIC Research Group. Update on cardiovascular outcomes at 30 years of the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37:39–43.
8. Gubitosi-Klug RA; DCCT/EDIC Research Group. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: summary and future directions. Diabetes Care. 2014;37:44–9.
9. Schofield D, Cunich MM, Shrestha RN, et al. The economic impact of diabetes through lost labour force participation on individuals and government: evidence from a microsimulation model. BMC Public Health. 2014;14:220.
10. Meyers JL, Parasuraman S, Bell KF, et al. The high-cost, type 2 diabetes mellitus patient: an analysis of managed care administrative data. Arch Public Health. 2014;72:6.
11. Asao K, Kaminski J, McEwen LN, et al. Assessing the burden of diabetes mellitus in emergency departments in the United States: The National Hospital Ambulatory Medical Care Survey (NHAMCS). J Diabetes Complic. 2014;S1056–8727:00047–56.
12. Gerich J. Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. Int J Gen Med. 2013;6:877–95.
13. Higgins JP, Thompson S. Quantifying heterogeneity in a meta-analysis. In: Higgins JP, Thompson S, editors. Statistics in Medicine. Hoboken: Wiley; 2002.
14. Li CJ, Li J, Zhang QM, et al. Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity. Cardiovasc Diabetol. 2012;11:142.
15. Forst T, Michelson G, Ratter F, et al. Addition of liraglutide in patients with Type 2 diabetes well controlled on metformin monotherapy improves several markers of vascular function. Diabet Med. 2012;29:1115–8.
16. Kaku K, Rasmussen MF, Clauson P, et al. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes. Diabetes Obes Metab. 2010;12:341–7.
17. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met + SU Study Group. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia. 2009;52:2046–55.
18. Marre M, Shaw J, Brändle M, et al. LEAD-1 SU study group. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26:268–78.
19. Zinman B, Gerich J, Buse JB, et al. LEAD-4 Study Investigators. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care. 2009;32:1224–30.
20. Nauck M, Frid A, Hermansen K, et al. LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32:84–90.
21. Seino Y, Rasmussen MF, Zdravkovic M, et al. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract. 2008;81:161–8.
22. Vilsbøll T, Brock B, Perrild H, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabetes Med. 2008;25:152–6.
23. Harder H, Nielsen L, Tu DT, et al. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care. 2004;27:1915–21.
24. Degn KB, Juhl CB, Sturis J, et al. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004;53:1187–94.
25. Panic N, Leoncini E, de Belvis G, et al. Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses. PLoS One. 2013;8:e83138.
26. Henning CH, Zarnekow N, Hedtrich J, et al. Identification of direct and indirect social network effects in the pathophysiology of insulin resistance in obese human subjects. PLoS One. 2014;9:e93860.
27. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes—causes, effects and coping strategies. Diabetes Obes Metab. 2007;9:799–812.
28. Muniyappa R, Sowers JR. Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord. 2013;14:5–12.
29. Bader G, Geransar P, Schweizer A. Vildagliptin more effectively achieves a composite endpoint of HbA1c < 7.0% without hypoglycaemia and weight gain compared with glimepiride after 2 years of treatment. Diabetes Res Clin Pract. 2013;100:e78–81.
30. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457–571.
31. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298:1189–95.
32. Kim SH, Liu A, Ariel D, et al. Pancreatic beta cell function following liraglutide-augmented weight loss in individuals with prediabetes: analysis of a randomised, placebo-controlled study. Diabetologia. 2014;57:455–62.
33. Luo X, Pan L, Nie A, et al. Liraglutide protects pancreatic beta cells during an early intervention in Gato-Kakizaki rats. J Diabetes. 2013;5:421–8.
34. Parthsarathy V, Hölscher C. Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model. PLoS One. 2013;8:e58784.
35. Elkhenini H, New JP, Summers LK, et al. Liraglutide therapy in obese people with type 2 diabetes—Experience of a weight management centre. Eur J Intern Med. 2014;25:e38–9.
36. Robinson LE, Holt TA, Rees K, et al. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open. 2013;3:e001986.
37. Wang B, Zhong J, Lin H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab. 2013;15:737–49.